文献速递青光眼

原发性选择性激光小梁成形术治疗开角型青光眼与高眼压症:青光眼与高眼压症激光试验的临床结局、成功预测因素与安全性

Primary Selective Laser Trabeculoplasty for Open-Angle Glaucoma and Ocular Hypertension: Clinical Outcomes, Predictors of Success, and Safety from the Laser in Glaucoma and Ocular Hypertension Trial.
PubMed 文献 · Ophthalmology · 2019-04-25

该研究是对多中心前瞻性随机对照试验的事后分析,纳入未治疗的开角型青光眼(OAG)或高眼压症(OHT)患者,比较原发性选择性激光小梁成形术(SLT)与局部降眼压药物的疗效。结果显示SLT在OHT与OAG眼早期绝对降眼压无差异,36个月时约74.6%眼达到无滴眼药疾病控制,多数仅需单次SLT,且安全性可接受。

要点

  • SLT在OHT与OAG眼早期绝对降眼压无差异(校正均差-0.05 mmHg,95%CI -0.6至0.5,P=0.85)。
  • 原发性SLT与局部药物早期绝对降眼压无差异(校正均差-0.1 mmHg,95%CI -0.6至0.4,P=0.67)。
  • 36个月时74.6%SLT治疗眼达到无滴眼药疾病控制,58.2%仅需单次SLT。

核心结论

  • 原发性SLT在OHT与OAG眼早期绝对降眼压效果相当,约75%眼在36个月时经1或2次SLT达到无滴眼药疾病控制,多数仅需单次SLT。
  • 这些分析为探索性,但支持原发性SLT对未治疗的OAG和OHT眼有效且安全。

研究设计与样本

  • 多中心、前瞻性、随机对照试验的事后分析。
  • 共611眼(195眼OHT和416眼OAG)来自355例患者接受SLT,622眼(185眼OHT和437眼OAG)来自362例患者接受局部降眼压药物。
  • 患者随机分配至SLT或局部药物治疗,并治疗至预设目标眼压,所有疾病严重程度均要求眼压较基线降低≥20%。

主要发现

  • SLT后早期绝对降眼压OHT眼与OAG眼无差异(校正均差-0.05 mmHg;95%CI -0.6至0.5 mmHg;P=0.85)。
  • 局部药物与原发性SLT早期绝对降眼压无差异(校正均差-0.1 mmHg;95%CI -0.6至0.4 mmHg;P=0.67)。
  • 原发性SLT早期绝对降眼压与基线眼压正相关(系数0.58;95%CI 0.53-0.63;P<0.001),与女性性别负相关(系数-0.63;95%CI -1.23至-0.02;P=0.04)。
  • 36个月时536眼(611眼中的87.7%)来自314例患者(355例中的88.5%)可进行分析;74.6%眼(400眼)经原发性SLT达到无滴眼药疾病控制,58.2%(312眼)仅需单次SLT。
  • 单次SLT后36个月无滴眼药疾病控制的预测因素包括总SLT能量和2个月眼压;6眼(6例患者)出现激光后即刻眼压升高(较治疗前眼压>5 mmHg),其中1眼需治疗。

关键数值与推荐

  • 所有疾病严重程度的目标眼压要求较基线降低≥20%。
  • 无滴眼药疾病控制定义为SLT后36个月内达到目标眼压且无疾病进展或无需额外局部药物。
  • 早期绝对降眼压定义为2个月时的绝对眼压降低。

临床怎么用

  • 原文结论认为这些探索性分析支持原发性SLT对未治疗的OAG和OHT眼有效且安全。

局限性

  • 原文明确称这些分析为探索性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report clinical efficacy, predictors of success, and safety of primary selective laser trabeculoplasty (SLT) used in treatment-naive patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). DESIGN: Post hoc analysis of a multicenter, prospective, randomized, controlled trial. PARTICIPANTS: Treatment-naive patients with OAG or OHT. METHODS: Patients randomized to SLT or topical medication and treated to predefined target intraocular pressures (IOPs) requiring ≥20% IOP reduction from baseline for all disease severity levels. OUTCOME MEASURES: Initial (early) absolute IOP-lowering at 2 months. Achievement of drop-free disease-control: meeting target IOP without disease progression or need for additional topical medication over 36 months after SLT. Predictors of early absolute IOP-lowering and drop-free disease-control after single initial SLT. Frequency of laser-related complications. RESULTS: A total of 611 eyes (195 OHT and 416 OAG) of 355 patients received SLT, and 622 eyes (185 OHT and 437 OAG) of 362 patients received topical medication at baseline. Early absolute IOP-lowering after SLT was no different between OHT and OAG eyes (adjusted mean difference = -0.05 mmHg; 95% confidence interval [CI], -0.6 to 0.5 mmHg; P = 0.85). No difference was noted in early absolute IOP-lowering between topical medication and primary SLT (adjusted mean difference = -0.1 mmHg; 95% CI, -0.6 to 0.4 mmHg; P = 0.67). Early absolute IOP-lowering with primary SLT was positively associated with baseline IOP (coefficient 0.58; 95% CI, 0.53-0.63; P < 0.001) and negatively with female gender (coefficient -0.63; 95% CI, -1.23 to -0.02; P = 0.04). At 36 months, 536 eyes (87.7% of 611 eyes) of 314 patients (88.5% of 355 patients) were available for analysis. Some 74.6% of eyes (400 eyes) treated with primary SLT achieved drop-free disease-control at 36 months; 58.2% (312 eyes) after single SLT. Total SLT power and 2-month IOP were predictors of drop-free disease-control at 36 months after single SLT. Six eyes of 6 patients experienced immediate post-laser IOP spike (>5 mmHg from pretreatment IOP) with 1 eye requiring treatment. CONCLUSIONS: Primary SLT achieved comparable early absolute IOP-lowering in OHT versus OAG eyes. Drop-free disease-control was achieved in approximately 75% eyes at 36 months after 1 or 2 SLTs, the majority of these after single SLT. These analyses are exploratory but support primary SLT to be effective and safe in treatment-naive OAG and OHT eyes.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Garg A, Vickerstaff V, Nathwani N, et al. Primary Selective Laser Trabeculoplasty for Open-Angle Glaucoma and Ocular Hypertension: Clinical Outcomes, Predictors of Success, and Safety from the Laser in Glaucoma and Ocular Hypertension Trial. Ophthalmology. 2019. PMID: 31028768. doi:10.1016/j.ophtha.2019.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。